70 related articles for article (PubMed ID: 1563535)
21. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
22. Effect of obesity on susceptibility to fatty acid-induced peripheral tissue insulin resistance.
Kruszynska YT; Olefsky JM; Frias JP
Metabolism; 2003 Feb; 52(2):233-8. PubMed ID: 12601639
[TBL] [Abstract][Full Text] [Related]
23. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.
Juhan-Vague I; Vague P; Alessi MC; Badier C; Valadier J; Aillaud MF; Atlan C
Diabete Metab; 1987 Jul; 13(3 Pt 2):331-6. PubMed ID: 3115843
[TBL] [Abstract][Full Text] [Related]
24. Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity.
Darmon P; Dadoun F; Boullu-Ciocca S; Grino M; Alessi MC; Dutour A
Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E995-E1002. PubMed ID: 16772320
[TBL] [Abstract][Full Text] [Related]
25. Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity?
Bastard JP; Bruckert E; Robert JJ; Ankri A; Grimaldi A; Jardel C; Hainque B
Int J Obes Relat Metab Disord; 1995 Nov; 19(11):836-8. PubMed ID: 8589788
[TBL] [Abstract][Full Text] [Related]
26. The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients.
Taniguchi A; Fukushima M; Sakai M; Kataoka K; Nagata I; Doi K; Arakawa H; Nagasaka S; Tokuyama K; Nakai Y
Metabolism; 2000 Aug; 49(8):1001-5. PubMed ID: 10954017
[TBL] [Abstract][Full Text] [Related]
27. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man.
Landin K; Tengborn L; Chmielewska J; von Schenck H; Smith U
Thromb Haemost; 1991 Feb; 65(2):130-3. PubMed ID: 1905068
[TBL] [Abstract][Full Text] [Related]
28. Relationships of plasminogen activator inhibitor activity and lipoprotein(a) with insulin, testosterone, 17 beta-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls.
Marques-Vidal P; Sie P; Cambou JP; Chap H; Perret B
J Clin Endocrinol Metab; 1995 Jun; 80(6):1794-8. PubMed ID: 7775625
[TBL] [Abstract][Full Text] [Related]
29. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.
Landin K; Stigendal L; Eriksson E; Krotkiewski M; Risberg B; Tengborn L; Smith U
Metabolism; 1990 Oct; 39(10):1044-8. PubMed ID: 2215252
[TBL] [Abstract][Full Text] [Related]
30. Normal plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal bypass surgery in morbidly obese individuals.
Sylvan A; Rutegård JN; Janunger KG; Sjölund B; Nilsson TK
Metabolism; 1992 Dec; 41(12):1370-2. PubMed ID: 1461144
[TBL] [Abstract][Full Text] [Related]
31. Elevated fibrinogen levels decrease following treatment of acromegaly.
Landin-Wilhelmsen K; Tengborn L; Wilhelmsen L; Bengtsson BA
Clin Endocrinol (Oxf); 1997 Jan; 46(1):69-74. PubMed ID: 9059560
[TBL] [Abstract][Full Text] [Related]
32. Influence of free testosterone on antigen levels of plasminogen activator inhibitor-1 in premenopausal women with central obesity.
De Pergola G; De Mitrio V; Perricci A; Cignarelli M; Garruti G; Lomuscio S; Ferri G; Schiraldi O; Giorgino R
Metabolism; 1992 Feb; 41(2):131-4. PubMed ID: 1736034
[TBL] [Abstract][Full Text] [Related]
33. Response of plasma insulin to small doses of tolbutamide in obesity and acromegaly.
Pelkonen R; Taskinen MR; Nikkilä EA
Int J Obes; 1977; 1(4):315-24. PubMed ID: 617112
[TBL] [Abstract][Full Text] [Related]
34. Non-insulin-mediated glucose uptake in several insulin-resistant states in the postabsortive period.
García-Estévez DA; Araújo-Vilar D; Cabezas-Cerrato J
Diabetes Res Clin Pract; 1998 Feb; 39(2):107-13. PubMed ID: 9597380
[TBL] [Abstract][Full Text] [Related]
35. Hypofibrinolysis and the insulin resistance syndrome.
Vague P; Raccah D; Scelles V
Int J Obes Relat Metab Disord; 1995 May; 19 Suppl 1():S11-5. PubMed ID: 7550531
[TBL] [Abstract][Full Text] [Related]
36. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease.
Landin K; Tengborn L; Smith U
J Intern Med; 1990 Apr; 227(4):273-8. PubMed ID: 2182759
[TBL] [Abstract][Full Text] [Related]
37. The relationships between insulin and plasminogen activator inhibitor 1 levels: assessment in groups of subjects with dyslipidaemia and hypertension.
Akanji AO; Al-Shayji I
Clin Chim Acta; 1998 Jun; 274(1):41-52. PubMed ID: 9681596
[TBL] [Abstract][Full Text] [Related]
38. Diet-induced changes in glucose and triglycerides are associated with changes in plasminogen activator inhibitor levels.
Sundell IB; Dahlén GH; Rånby M
Haemostasis; 1991; 21(3):175-80. PubMed ID: 1837785
[TBL] [Abstract][Full Text] [Related]
39. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.
Juhan-Vague I; Alessi MC; Vague P
Diabetologia; 1991 Jul; 34(7):457-62. PubMed ID: 1916049
[TBL] [Abstract][Full Text] [Related]
40. Inverse relationship between cortisol excretion rate and plasminogen activator inhibitor-1 (PAI-1) antigen and activity in premenopausal obese women.
De Pergola G; De Mitrio V; Cignarelli M; Garruti G; Giorgino F; Meola M; Giorgino R
Int J Obes; 1991 Sep; 15(9):619-22. PubMed ID: 1960012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
